Koelle D M, Schomogyi M, McClurkan C, Reymond S N, Chen H B
Department of Medicine, University of Washington, Seattle, Washington 98105, USA.
J Virol. 2000 Dec;74(23):11422-5. doi: 10.1128/jvi.74.23.11422-11425.2000.
We used CD4 lymphocyte clones from herpes simplex virus type 2 (HSV-2) lesions or the cervix and molecular libraries of HSV-2 DNA to define HSV-2 major capsid protein VP5 and glycoprotein E (gE) as T-cell antigens. Responses to eight HSV-2 glycoprotein, tegument, nonstructural, or capsid antigens were compared in 19 donors. Recognition of VP5 and tegument VP22 were similar to that of gB2 and gD2, currently under study as vaccines. These prevalence data suggest that HSV capsid and tegument proteins may also be candidate vaccine antigens.
我们使用来自2型单纯疱疹病毒(HSV-2)损伤部位或子宫颈的CD4淋巴细胞克隆以及HSV-2 DNA分子文库,将HSV-2主要衣壳蛋白VP5和糖蛋白E(gE)定义为T细胞抗原。在19名供体中比较了对8种HSV-2糖蛋白、被膜、非结构或衣壳抗原的反应。对VP5和被膜蛋白VP22的识别与目前作为疫苗正在研究的gB2和gD2相似。这些流行率数据表明,HSV衣壳蛋白和被膜蛋白也可能是候选疫苗抗原。